US SB2760

Amends Medicare (Title XVIII of the Social Security Act) to cover germline mutation genetic testing for individuals with a family history of hereditary cancer gene mutations or personal/ancestral history suspicious for hereditary cancer

Requires genetic testing to follow evidence-based clinical practice guidelines from nationally recognized oncology organizations including the National Comprehensive Cancer Network, American Society of Clinical Oncology, and Society of Gynecologic Oncology

Covers risk-reducing preventive surgeries for individuals with germline mutations when clinical guidelines indicate surgery would reduce cancer risk, classifying such procedures as "reasonable and necessary" under Medicare

Increases frequency of cancer screenings (mammography, breast MRI, colonoscopy, PSA testing) for individuals with confirmed hereditary cancer gene mutations to at least annual basis, overriding standard Medicare frequency limitations

Introduced September 10, 2025 by Senators Murkowski (R-AK) and Slotkin (D-MI), referred to Senate Committee on Finance; effective upon enactment